AboutKarl Karlsson, PhD

A lead on Sg2’s custom solutions Consulting team, Karl leverages more than 7 years of experience developing domestic and international health care strategies. He scopes, leads and delivers customized strategic and operational planning engagements, with particular expertise in ambulatory strategy development, facility planning, service line analysis and technology adoption. Karl also works closely with Sg2’s international clients in the United Kingdom, Australia and Southeast Asia.

Examples of Karl’s recent engagements include developing inpatient and ambulatory strategies for over 60 hospitals in 15 markets across the United States for a large for-profit health system. He also conducted a feasibility assessment for a potential merger between a for-profit health system and an academic medical center; developed network strategies for a clinically integrated 3-hospital system in the Southeastern US; built a strategic prioritization framework for a nonprofit multihospital health system in the Western US; and constructed the oncology medical tourism strategy for one of the largest private hospitals in Southeast Asia.

Karl earned a PhD from the University of Oxford in the United Kingdom, where he researched and developed in vitro models to study HIV infection. In 2004, he worked at the Gladstone Institute in San Francisco, CA, where he investigated mechanisms of resistance to HIV. He received a BSc in biomedical sciences and pharmacology from King’s College London.

"Analytics and expertise to help you understand market dynamics and capitalize opportunities for growth."

As of February 11, 2016, Vizient, Inc. has completed its purchase of MedAssets Sg2 and spend and clinical resource management segments from Pamplona Capital Management, LLC. MedAssets revenue cycle business will continue to operate as a wholly-owned subsidiary of Pamplona Capital Management LLP.

Follow Sg2 on Twitter Connect with Sg2 on LinkedIn Watch Sg2 on YouTube